Veeva SystemsWBO:VEEV +5.25%84 EBITDA Margin % is 32.24% as of Apr. 2026, which is 19% above its 10-year median of 27.05. GuruFocus rates WBO:VEEV with a GF Score™ of 84/100 and a GF Value™ of €254.11 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 668 Healthcare Providers & Services companies, Veeva Systems ranks better than 90.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Veeva Systems's EBITDA for the
three
months ended in Apr. 2026 was €243 Mil. Veeva Systems's Revenue for the
three
months ended in Apr. 2026 was €755 Mil. Therefore, Veeva Systems's EBITDA margin for the quarter that ended in Apr. 2026 was 32.24%.
Veeva Systems (WBO:VEEV) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Veeva Systems EBITDA Margin % Related Terms
Veeva Systems EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Veeva Systems's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VEEV vs BTSG, TEM, HQY: EBITDA Margin % Comparison
For the Health Information Services subindustry, Veeva Systems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Veeva Systems's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veeva Systems (WBO:VEEV) has a EBITDA Margin % of 32.24% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veeva Systems and its competitors. This is 19% above median its historical median of 27.05. Over the past decade, Veeva Systems' EBITDA Margin % has ranged from 19.54 to 29.99. According to the industry distribution chart, Veeva Systems ranks #63 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 9.4%.
Is Veeva Systems' EBITDA Margin % too high?
Veeva Systems' current EBITDA Margin % of 32.24% is 19% above median its 10-year median of 27.05. Over the past 10 years, this metric has ranged from a low of 19.54 to a high of 29.99. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Veeva Systems' value of 32.24% is 215.8% above this industry median. Based on the distribution chart, Veeva Systems ranks #63 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Veeva Systems has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' EBITDA Margin % compare to BTSG and TEM?
According to the Healthcare Providers & Services industry distribution chart, Veeva Systems ranks #63 out of 668 companies for EBITDA Margin %. This places Veeva Systems in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Veeva Systems' value of 32.24% is 215.8% above this benchmark. Historically, Veeva Systems' own EBITDA Margin % has ranged from 19.54 to 29.99 over the past decade. While the company's 10-year median is 27.05 vs. the industry median of 10.21, Veeva Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current EBITDA Margin % of 32.24% is 215.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current EBITDA Margin % is 32.24%, which is 19% above median its own 10-year median of 27.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (WBO:VEEV) is currently considered Significantly Undervalued. The stock's GF Value™ is €254.11, compared to a current price of €148.25 — trading 41.7% below its estimated fair value. The current EBITDA Margin % is 32.24%, which is 19% above median its 10-year median of 27.05 and 215.8% above the Healthcare Providers & Services industry median of 10.21. Veeva Systems' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Veeva Systems (WBO:VEEV), the current EBITDA Margin % is 32.24% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (WBO:VEEV) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of €148.25 is trading 41.7% below its estimated GF Value™ of €254.11.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for WBO:VEEV:
EBITDA Margin %: 32.24% (19% above median its 10-year median of 27.05)
GF Value™: €254.11 vs. price of €148.25 (41.7% below fair value)
Industry Position: 215.8% above the Healthcare Providers & Services median (#63 of 668)
No single metric tells the full story. See the WBO:VEEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
84GF Score
Get the complete analysis for WBO:VEEV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VEEV has been successfully added to your 
